JPWO2022149549A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022149549A5 JPWO2022149549A5 JP2022574041A JP2022574041A JPWO2022149549A5 JP WO2022149549 A5 JPWO2022149549 A5 JP WO2022149549A5 JP 2022574041 A JP2022574041 A JP 2022574041A JP 2022574041 A JP2022574041 A JP 2022574041A JP WO2022149549 A5 JPWO2022149549 A5 JP WO2022149549A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acid
- group
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims description 12
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 39
- 150000001413 amino acids Chemical class 0.000 claims 27
- 108091008874 T cell receptors Proteins 0.000 claims 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 14
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 229940024606 amino acid Drugs 0.000 claims 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 5
- 210000001808 exosome Anatomy 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 5
- 241001678559 COVID-19 virus Species 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 108091092584 GDNA Proteins 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 208000025721 COVID-19 Diseases 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims 1
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 claims 1
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 230000009258 tissue cross reactivity Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021000382 | 2021-01-05 | ||
| PCT/JP2021/017162 WO2022149295A1 (ja) | 2021-01-05 | 2021-04-30 | ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン |
| US202163236927P | 2021-08-25 | 2021-08-25 | |
| PCT/JP2021/048846 WO2022149549A1 (ja) | 2021-01-05 | 2021-12-28 | ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022149549A1 JPWO2022149549A1 (https=) | 2022-07-14 |
| JPWO2022149549A5 true JPWO2022149549A5 (https=) | 2025-01-07 |
Family
ID=82357762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574041A Pending JPWO2022149549A1 (https=) | 2021-01-05 | 2021-12-28 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20240067679A1 (https=) |
| JP (1) | JPWO2022149549A1 (https=) |
| WO (1) | WO2022149549A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7598538B2 (ja) * | 2021-01-29 | 2024-12-12 | 東亞合成株式会社 | ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 |
| JPWO2024085143A1 (https=) * | 2022-10-17 | 2024-04-25 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11203783B2 (en) * | 2013-11-21 | 2021-12-21 | Repertoire Genesis Incorporation | T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis |
| CN112034174B (zh) * | 2020-03-20 | 2024-03-29 | 中国人民解放军军事科学院军事医学研究院 | 一种多肽芯片及其在病毒检测上的应用 |
-
2021
- 2021-12-28 WO PCT/JP2021/048846 patent/WO2022149549A1/ja not_active Ceased
- 2021-12-28 JP JP2022574041A patent/JPWO2022149549A1/ja active Pending
- 2021-12-28 US US18/270,590 patent/US20240067679A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518821A (ja) | コロナウイルスのワクチンと使用方法 | |
| CN107074970B (zh) | 特异性针对wt-1的t细胞免疫疗法 | |
| CN100560130C (zh) | 基于癌抑制基因wt1的产物的癌抗原 | |
| TW200906850A (en) | TEM8 peptides and vaccines comprising the same | |
| JP2016511221A5 (https=) | ||
| RU2012127358A (ru) | Олигопептиды imp-3 и содержащие их вакцины | |
| JP5339375B2 (ja) | Ｆｏｘｐ３ペプチドワクチン | |
| JPWO2022149549A5 (https=) | ||
| TW201000115A (en) | IQGAP3 epitope peptides and vaccines containing the same | |
| CN106243213B (zh) | 一种肿瘤相关抗原XAGE-1b短肽及应用 | |
| RU2015143164A (ru) | Пептиды kntc2 и содержащие их вакцины | |
| JP2014533095A5 (https=) | ||
| CN104619833B (zh) | Ube2t肽及包含它们的疫苗 | |
| JP2015529219A5 (https=) | ||
| CN106279392B (zh) | 肿瘤相关抗原XAGE-1b短肽及其应用 | |
| JP2011504875A (ja) | Ｓｔａｔ３エピトープペプチド | |
| WO2016093243A1 (ja) | 腫瘍抗原ペプチド | |
| CN102264897B (zh) | Rab6kifl/kif20a表位肽及包含它的疫苗 | |
| KR20160111973A (ko) | 인간 t 림프영양성 바이러스 타입 1에 대한 면역 반응들을 발생시키기 위한 렌티바이러스 벡터들 | |
| JPWO2022071435A5 (https=) | ||
| US20240067679A1 (en) | Sars-cov-2 protein-derived peptide and vaccine containing same | |
| RU2022100330A (ru) | Пептид, полученный из depdc1, и содержащая его вакцина | |
| JP4780540B2 (ja) | サバイビン由来癌抗原ペプチド | |
| JPWO2020027239A5 (https=) | ||
| JP2023543878A (ja) | Ｂｏｂ１に対するｔ細胞受容体およびその使用 |